贝纳利祖马布在异位膜炎带有异位膜炎的eosinophilic granulomatosis中的长期有效性
Alexandra M Nanzer1, Anne-Catherine Maynard-Paquette2, Vardah Alam1
1Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Trust, London, United Kingdom; School of Immunology & Microbial Sciences, King's College London, London, United Kingdom.
The journal of allergy and clinical immunology. In practice
|January 11, 2024
概括
贝纳利祖马布治疗有效诱导临床缓解和皮质类固醇免费状态在大多数患有聚炎 (EGPA) 带来的埃索诺菲尔粒状瘤症的患者中. 这项现实研究表明,本拉利祖马布耐受性良好,对EGPA管理有益.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 肺部病理学 肺部病理学
背景情况:
- 带有多炎的埃索诺菲尔颗粒炎 (EGPA) 是一种严重的多系统性疾病,以埃索诺菲尔炎症为特征.
- 贝纳利祖马布是一种抗列素-5受体 (抗IL-5R) 单克隆抗体,有效地消耗乙氨基,但其对EGPA的长期影响尚未得到充分证实.
研究的目的:
- 评估本拉利祖马布在EGPA患者中实现临床缓解的实际有效性.
- 评估EGPA患者在两年内用本拉利祖马布治疗的临床缓解和复发率.
主要方法:
- 一项回顾性队列研究分析了用本拉利祖马布治疗的EGPA患者.
- 临床缓解被定义为无血管炎 (BVAS=0) 和低剂量口服皮质类固醇 (OCS ≤4 mg/d).
- 评估了复发率,皮质类固醇缓解效应和患者报告的结果.
主要成果:
- 70名患者中有67.1%的患者在1年内实现了临床缓解,在2年后的比例相似.
- 87.1%的患者在1年内没有复发 (不包括喘复发),67.9%的患者实现了无皮质类固醇状态.
- 本拉利祖马布耐受性良好,ANCA阳性和ANCA阴性亚组之间没有显著差异.
结论:
- 在现实世界中,本拉利祖马布是对EGPA的耐受性良好且有效的治疗方法.
- 大多数接受本拉利祖马布治疗的EGPA患者实现了持续的临床缓解,并且可以停止服用口服皮质类固醇.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
299
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
299
01:19Antiasthma Drugs: Leukotriene Modifiers
302
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
302
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
166
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
166
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
267
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
267